Millions of individuals suffering from life-threatening heart conditions rely on cardiac implantable electronic devices (CIEDs), such as pacemakers or implantable cardioverter defibrillators (ICDs), to manage abnormal heart rhythms1. However, like any surgical procedure, the risk of infection is a significant concern that affects patient outcomes and healthcare costs. In an effort to address this challenge, an innovative solution has emerged: the Absorbable antibacterial Envelope.
Dr. Prem Krishna, Associate Professor of Cardiology at PSG Institute of Medical Sciences & Research, Coimbatore, explains, "CIED infections pose a substantial threat to patients, leading to increased morbidity, mortality, and financial burdens. The Absorbable antibacterial Envelope offers a promising approach to stabilize cardiac implants and significantly reduce the risk of infections associated with these devices."
Multiple studies have demonstrated the significant benefits of using the Antibacterial Envelope for patients at high risk of heart device infection. These studies reveal infection reductions ranging from 70% to 100% compared to similar patients who did not receive the Antibacterial Envelope3-7. Moreover, cost-effectiveness analyses have shown that adopting the Absorbable antibacterial Envelope as part of infection prevention strategies in the U.S. healthcare system offers considerable financial advantages over standard-of-care approaches.